GL1X · GenesisL1 explorer

Research workbench

Drug resistant csrc kinase domain in complex with covalent inhibitor PD168393

Analyse Drug resistant csrc kinase domain in complex with covalent inhibitor PD168393 in the GL1X research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides, crosslinks and neighbours on the 3D structure.

PDB
3LOK
Type
protein
Length
490 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Proto-oncogene tyrosine-protein kinase src
EC
2.7.10.2
UniProt
P00523
Ligands
DJK
Pockets
5 · best druggability 0.65

Structure

x-ray diffraction · 2 distinct chains · 38% helix, 17% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
AProto-oncogene tyrosine-protein kinase src (EC 2.7.10.2)protein24839% helix, 16% strandP00523
BProto-oncogene tyrosine-protein kinase src (EC 2.7.10.2)protein24237% helix, 17% strandP00523

Ligands and binding sites

  • DJK · N-[4-(3-bromo-phenylamino)-quinazolin-6-yl]-acrylamide · ligand · 2 copies · chains A, B

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

5 pockets found on a 1 Å grid, 3 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
15450.650.7667DJK
25030.640.7746empty
31640.540.8023DJK
4680.490.8317empty
51130.350.7323empty

Interfaces

1 interface between chains.

  • A–B · 356 Ų buried · 5 hydrogen bonds · protein-protein

Modifications

Observed in the structure: 2 covalent (covalent ligand).

Compared structures

  • 3LOK · Drug resistant cSrc kinase domain in complex with covalent inhibitor PD168393 · the same entry in another collection · chain A against A, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.